Browse

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

DC Field Value Language
dc.contributor.authorRothenberg, M. L.-
dc.contributor.authorCox, J. V.-
dc.contributor.authorButts, C.-
dc.contributor.authorNavarro, M.-
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorGoel, R.-
dc.contributor.authorGollins, S.-
dc.contributor.authorSiu, L. L.-
dc.contributor.authorLaguerre, S.-
dc.contributor.authorCunningham, D.-
dc.date.accessioned2021-01-31T11:08:52Z-
dc.date.available2021-01-31T11:08:52Z-
dc.date.issued2008-10-
dc.identifier.citationAnnals of Oncology, Vol.19 No.10, pp.1720-1726-
dc.identifier.issn0923-7534-
dc.identifier.other119535-
dc.identifier.urihttps://hdl.handle.net/10371/173058-
dc.description.abstractBackground: To demonstrate the noninferiority of capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid and oxaliplatin (FOLFOX-4) as second-line therapy in patients with metastatic colorectal cancer after prior irinotecan-based chemotherapy. Patients and methods: A total of 627 patients were randomly assigned to receive XELOX (n = 313) or FOLFOX-4 (n = 314) following disease progression/recurrence or intolerance to irinotecan-based chemotherapy. The primary end point was progression-free survival (PFS). Results: PFS for XELOX was noninferior to FOLFOX-4 [hazard ratio (HR) = 0.97; 95% confidence interval (CI) 0.83-1.14] in the intention-to-treat (ITT) population. Median PFS was 4.7 months with XELOX versus 4.8 months with FOLFOX-4. The robustness of the primary analysis was supported by multivariate and subgroup analyses. Median overall survival in the ITT population was 11.9 months with XELOX versus 12.5 months with FOLFOX-4 (HR = 1.02; 95% CI 0.86-1.21). Treatment-related grade 3/4 adverse events occurred in 50% of XELOX- and 65% of FOLFOX-4-treated patients. Whereas grade 3/4 neutropenia (35% versus 5% with XELOX) and febrile neutropenia (4% versus < 1%) were more common with FOLFOX-4, grade 3/4 diarrhea (19% versus 5% with FOLFOX-4) and grade 3 hand-foot syndrome (4% versus < 1%) were more common with XELOX. Conclusion: XELOX is noninferior to FOLFOX-4 when administered as second-line treatment in patients with metastatic colorectal cancer.-
dc.subjectcapecitabine-
dc.subject5-fluorouracil/folinic acid-
dc.subjectFOLFOX-4-
dc.subjectmetastatic colorectal cancer-
dc.subjectoxaliplatin-
dc.subjectXELOX-
dc.titleCapecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study-
dc.typeArticle-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.1093/annonc/mdn370-
dc.citation.journaltitleAnnals of Oncology-
dc.identifier.scopusid2-s2.0-53049092394-
dc.citation.endpage1726-
dc.citation.number10-
dc.citation.startpage1720-
dc.citation.volume19-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0923753419401865?via%3Dihub-
dc.identifier.rimsid119535-
dc.identifier.sci000259581200008-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse